Press Release
Bolt Biotherapeutics Announces Initiation of BDC-1001 Clinical Trial in Patients with HER2-Expressed Solid Tumors
Bolt Biotherapeutics Announces Initiation of BDC-1001 Clinical Trial in Patients with HER2-Expressed Solid Tumors
Bolt Biotherapeutics Appoints Dr. Nils Lonberg to its Scientific Advisory Board
Bolt Biotherapeutics Expands Scientific Advisory Board with Appointment of Dr. Priti Hegde
Bolt Biotherapeutics Presents Data At SITC Conference Showing Eradication of Large Tumors in Preclinical Studies
Bolt Strengthens Scientific Advisory Board Through Addition of Drs. Lawrence Fong, Roy Herbst and Bruce Roth
Randall Schatzman, Ph.D., joins Bolt Biotherapeutics as CEO and a member of the board of directors, bringing over 30 years of biotech industry leadership experience
Bolt Biotherapeutics Presents Preclinical Proof of Concept Data at American Association for Cancer Research (AACR) Conference
Bolt Biotherapeutics Completes $54 Million Series B Financing